NeoPharm CO. LTD (092730) — Free Cash Flow Generation Index
NeoPharm CO. LTD (092730) has a Free Cash Flow Generation Index of 0.92x as of September 2025. Free cash flow of ₩5.43 Billion represents 1% of operating cash flow (₩5.88 Billion). Explore how much does NeoPharm CO. LTD reinvest in capital to see what proportion of operating cash flow is directed to capital expenditures.
FCF Generation Index
Free Cash Flow
Operating Cash Flow
Capital Expenditures
NeoPharm CO. LTD Free Cash Flow Generation Index (2012–2024)
Historical FCF Generation Index trend for NeoPharm CO. LTD across 11 annual periods. For the full cash flow conversion analysis, see cash flow conversion of NeoPharm CO. LTD.
Annual Free Cash Flow Generation for NeoPharm CO. LTD (2012–2024)
Year-by-year Free Cash Flow Generation Index for NeoPharm CO. LTD. Check how aggressively does NeoPharm CO. LTD reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
| Year | FCG Index | Free Cash Flow (KRW) | Operating CF | Capital Expenditures | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.83x | ₩15.55 Billion | ₩18.63 Billion | ₩3.08 Billion | ▲ +697.6% |
| 2023 | 0.10x | ₩2.43 Billion | ₩23.26 Billion | ₩20.83 Billion | ▼ -89.0% |
| 2022 | 0.96x | ₩17.35 Billion | ₩18.16 Billion | ₩806.43 Million | ▼ -2.3% |
| 2021 | 0.98x | ₩21.20 Billion | ₩21.68 Billion | ₩320.11 Million | ▲ +2.2% |
| 2020 | 0.96x | ₩16.34 Billion | ₩17.07 Billion | ₩285.62 Million | ▼ -17.5% |
| 2019 | 1.16x | ₩22.31 Billion | ₩19.22 Billion | ₩5.90 Billion | ▲ +3.6% |
| 2018 | 1.12x | ₩18.12 Billion | ₩16.18 Billion | ₩1.94 Billion | ▲ +3.4% |
| 2017 | 1.08x | ₩11.53 Billion | ₩10.65 Billion | ₩884.71 Million | ▼ -6.1% |
| 2016 | 1.15x | ₩10.56 Billion | ₩9.16 Billion | ₩1.40 Billion | ▲ +2.2% |
| 2015 | 1.13x | ₩6.88 Billion | ₩6.09 Billion | ₩786.89 Million | ▼ -13.5% |
| 2012 | 1.31x | ₩736.81 Million | ₩564.34 Million | ₩172.47 Million | — |